Objective: To establish a method to investigate pharmacokinetics and bioequivalence of domestic flurbiprofen axetil injection. Methods: An open, randomized, and two-cycle crossover study was conducted in 24 healthy volunteers. Plasma concentrations of flurbiprofen were determined by LC-MS/MS after administering a single dose of reference drug or test drug. Main pharmacokinetic parameters were calculated by using Phoenix Win Nonlin(V8.1) software. Results: For the test drug and the reference drug, the main pharmacokinetic parameters of flurbiprofen were as follows: AUC_(0-t)was(27 644.02 ± 6 243.692) min · ng · ml-1 and(28 108.34 ±5 591.351) min·ng·ml∼(-1), AUC_(0-∞)was(28 606.46 ± 6 876.757) min·ng·ml∼(-1) and(29 040.66 ± 6 077.130) min·ng·ml-1, Cmax was(9 349.17±1 161.303) ng·ml∼(-1) and(9 415.42±1 228.077) ng·ml∼(-1), and the median of Tmaxwas 0.07 h and 0.05 h, resp. Under two kinds of conditions, 90% CIs of AUC_(0-t), AUC_(0-∞)and Cmaxof the test preparation were 80%-125% of the corresponding parameters of the reference preparation, and there was no statistical significance in Tmaxbetween the two preparations(P>0.05). Conclusion: The test drug and the reference drug are bioequivalent.